Clinical trials: NSCLC Patients With Brain Metastasis, open to volunteers
Lung Cancer (NSCLC)
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07083687
- Testing
- Lorlatinib 100 mg
- Volunteers
- 21 people
- Sponsor
- Hunan Cancer Hospital
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well it works in determining treatment response for patients with stage IV…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07619599
- Testing
- Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer (NSCLC), Brain Metastases
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Trial name
- NCT07365410
- Testing
- Furmonertinib, carboplatin, pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal…
- Trial name
- NCT07304739
- Testing
- Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
NSCLC Stage IV, Brain Metastases, Adult
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease…
- Trial name
- NCT06401824
- Testing
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht University Medical Center
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
Non-small Cell Lung Cancer Patients with Brain Metastases
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
This study is a prospective, multicenter, two-stage phase II clinical trial evaluating the efficacy and safety of Utidelone combined with Bevacizumab in patients with non-small cell lung cancer with brain metastases.
- Trial name
- NCT06683703
- Testing
- Utidelone combined with Bevacizumab, Utidelone
- Volunteers
- 118 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
The goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in NSCLC patients with brain metastases by deep learning, as well as common clinicopathological parameters, which…
- Trial name
- NCT06604689
- Testing
- third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Fudan University
NSCLC, EGFR Activating Mutation
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
- Conditions
- NSCLC, EGFR Activating Mutation, Brain Metastases
- Trial name
- NCT05948813
- Testing
- TY-9591, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- TYK Medicines, Inc
NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated…
- Conditions
- NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Trial name
- NCT07755397
- Testing
- JBI-778
- Where
- 6 sites in India
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics India Limited
Non Small Cell Lung Cancer Metastatic
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
- Trial name
- VULCAN (NCT05864794)
- Testing
- MRI
- Where
- 3 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- University Medical Center Groningen
Seizures, Primary Motor Cortex
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or…
- Conditions
- Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult
- Trial name
- NCT07130786
- Testing
- Levetiracetam (Keppra)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ayal A. Aizer, MD
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
NSCLC, Brain Metastases
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS…
- Conditions
- NSCLC, Brain Metastases, ROS1 Gene Rearrangement
- Trial name
- REPOSE (NCT06315010)
- Testing
- Repotrectinib
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- MedSIR
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Non-small Cell Lung Cancer, Brain Metastases
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
The goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus concomitant transdermal nitroglycerin (NTG) addition…
- Conditions
- Non-small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- NCT06238882
- Testing
- Nitroglycerin
- Where
- Mexico
- Volunteers
- 74 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-Small Cell Lung Cancer, Brain Metastases
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
This retrospective multicenter observational study aims to develop and externally validate a noninvasive deep learning model based on routine brain MRI to identify actionable driver alterations in patients with non-small cell…
- Trial name
- DL-DriverBM (NCT07373951)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Ming Yang
Non Small Cell Lung Cancer Metastatic
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC.
- Trial name
- NCT06741085
- Testing
- osimertinib, stereotactic radiosurgery (SRS)
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center